Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
On the scout for next infectious disease thx.
Tonya Villafana
Vice President, Global Franchise Head, Infection
Linkedin
Combining my academic training in immunology and public health experience, I am responsible for leading cross-functional global product development teams for vaccines and monoclonal antibodies. This includes, but is not limited to, AZD1222 (ChAdOx1-S vaccine for SARS-CoV-2) and MEDI8897 (nirsevimab for respiratory syncytial virus).
As the Global Franchise Lead for Infectious Diseases and a Global Product Lead, I work within BioPharmaceuticals R&D to explore potential new vaccines and drugs to prevent or to treat infectious diseases in the most vulnerable populations globally. I collaborate closely with a number of important external stakeholders at a global level, including public health organisations, regulatory authorities, and government representatives and healthcare policymakers on key development milestones from early development to launch of product.
During my career, I have served on several scientific committees and advisory boards including the Malaria Clinical Trials Alliance, International Society for Vaccines and the NIH Integrated Preclinical/Clinical AIDS Vaccine Development Program. I have worked closely on global health initiatives with the World Bank, the Bill and Melinda Gates Foundation, PAHO, WHO, IFPMA, and the UK Development Agency for International Development. I have been fortunate to work in countries around the world, both in high income and low income settings which enables me to have significant perspective on how best to address the needs of different populations.
I received a PhD in immunology from Weill Cornell University Graduate School of Medical Sciences and an MPH from Harvard School of Public Health.
Look we all agree Synairgen are now joining the dots and pressing forward with more development/commercial options and avenues on all severe respiratory diseases so in that sense we are refining our go to market strategy for sure but a pivotal ingredient must be covid and all its longer term health and economic implications
It's because they kind of know we have a knock out therapeutic in the event of a seriously severe mutant variant coming down the genetic pipeline so to speak that will side-step many other treatment modalities and vaccine conformations and combinations. So any forward thinking Government would be stupid to want to go back to lock downs and further massivw economic disruption. When will they learn...long term prevention decisions are much superior to short term reactive ones with viral pathogens. Get real.
We are only in real trouble Doc should any said new variant strain buck the trend and up its game in terms of severity characteristics. We will see that eventually due to natural darwin genetic selection / variation or random event permutations but alas our UK Government will never stockpile SNG001 in the (high) chance of that outcome in practice. KB was a scientific/VC pawn in the Government Covid response game (with blinkers on in fact limited to vaccine response ONLY). Books mean nothing really other than self promotion in this case limited by Government ineptitude.
Given all investors on the back foot and burnt we now have a clear asymmetric intrinsic value gap to the share price since we are all heavily invested. Big rise inbound this year for sure for those with spate cash under sofa!
BTW and people can self dose at home to avoid onward transmission in case of severe emerging respiratory viral threats. You just mail this therapy to the vulnerable and most at risk parts of population in the over 60s age group. Just think out of the box.
There's a surprise I WAS expecting. Fabulous as a very wide complete repertoire agnostic antiviral. mutation defence and economic defence written all over the SNG 001 packaging. ..
This is a highly volatile stock we are seeing in practice Andy - if you get the chance to buy in low before the next upswing good luck to you. I'm guessing you're not solely gloating without some desire to buy back in after you scare investors to give you shares at under value? Plenty of possible upside events can still evolve to balance your disaster scenario in coming weeks and months before SNG goes lights out right?. Just enjoy the ride.....have fun
Smartinvestor. I did think of that derisking possibility also but did not articulate it. The delay to progression in the stock consolidation is curious to me too but maybe explainable should it align to a value driving news announcement. This could allow better share price outcome and US investor demand via timely fusion of the two. ..mmmm. we wait to see .